Real-world Outcomes Associated With Poly(ADP-ribose) Polymerase Inhibitor Monotherapy Maintenance in Patients With Primary Advanced Ovarian Cancer.

John K Chan,Jinan Liu,Jinlin Song,Cheryl Xiang,Eric Wu,Linda Kalilani,Jean A Hurteau,Premal H Thaker

American journal of clinical oncology（2023）

引用 0|浏览8

暂无评分

摘要

Our real-world analysis suggested that 47% of patients with primary AOC did not receive PARPi maintenance in the year 2021. PARPi use was associated with significantly improved outcomes compared with AS.

查看译文

关键词

PARP inhibitor, advanced ovarian cancer, first-line, monotherapy, real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要